A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 16, 2020

Study Completion Date

December 16, 2020

Conditions

Relapsed or Refractory Neuroblastoma

Interventions

OTHER

Leukapheresis

DRUG

Cyclophosphamide

DRUG

Fludarabine

GENETIC

1RG-CART

Trial Locations (1)

University College London Institute of Child Health & Great Ormond Street Hospital, London